Use of Corifolitropin Alfa in Oocyte Donors
Female Reproductive Problem, Infertility
About this trial
This is an interventional treatment trial for Female Reproductive Problem focused on measuring Corifollitropin alfa, recombinant FSH, HP-hMG, apoptosis, oocyte donation
Eligibility Criteria
Inclusion Criteria:
- Women aged 18-35 years who meet the entry criteria for the IVI Donor Program:
- Weight < 60 Kg
- Women with at least 6 antral follicles per ovary
- Women who will fit the protocoo during the period of the study
- Women who give written consent to participate in the test
Exclusion Criteria:
- Women with basal antral follicle count above 20 or below 6.
- Women with comorbidities, in the judgement of the investigator, that may interfere with the trearment of ovarian stimulation.
Sites / Locations
- IVI MadridRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Corifollitropin alfa
Recombinant FSH
HP-hMG
From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.